ISPOR - PND3 COST-UTILITY ANALYSIS OF NATALIZUMAB AS FIRST LINE THERAPY FOR HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS FROM A BRAZILIAN PRIVATE PAYER PERSPECTIVE

PND3 COST-UTILITY ANALYSIS OF NATALIZUMAB AS FIRST LINE THERAPY FOR HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS FROM A BRAZILIAN PRIVATE PAYER PERSPECTIVE

Abstract

Authors

L. Fahham R. Rosim J. Rigolon

Full Text Cite This Article

Back to Volume 19, Supplemental S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now